Network Pharmacology Reveals MAPK- and RTK-mediated Erythropoietic Signalling as a Shared Mechanism of Dapagliflozin and Empagliflozin
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors consistently raise haemoglobin and haematocrit in patients with type 2 diabetes, heart failure and chronic kidney disease, and post-hoc mediation analyses suggest that this haematological shift accounts for a substantial fraction of their cardiovascular benefit. Th...